Significant response to pralsetinib in a medullary thyroid cancer harboring double RET variants of unknown significance.

Hescot, Ségolène; Masliah-Planchon, Julien; du Rusquec, Pauline; Dupain, Célia; Kamal, Maud; Servois, Vincent; Bieche, Ivan.

Afiliação

Hescot S; Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France.
Masliah-Planchon J; Department of Genetics, Institut Curie, Paris, France.
du Rusquec P; Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France.
Dupain C; Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France.
Kamal M; Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France.
Servois V; Department of Radiology, Institut Curie, Paris, France.
Bieche I; Department of Genetics, Institut Curie, Paris, France.

Eur Thyroid J ; 11(5)2022 Oct 01.

Article em En | MEDLINE | ID: mdl-36053791

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article